Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Eli Lilly (NYSE:LLY) shares dropped on Thursday after lowering its full-year outlook amid a decision by CVS Health (NYSE:CVS) ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

This marks a shift in the agency's approach to treating the global obesity problem. Read more at straitstimes.com. Read more ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

CVS Health will drop the weight-loss drug Zepbound from its insured pharmacy options this summer. Employers and insurers may ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.